Inflammation, Brain Clinical Trial
The protocol is to draw peripheral blood from healthy volunteers for in vitro studies. The aims of these in vitro studies are to determine the cellular and intracellular mechanisms by which hypertonic saline and ATP release regulate neutrophil and lymphocyte functions.
The proper regulation of leukocyte function is critical for immune defense and to prevent
autoimmune diseases. Many aspects of immune cell regulation are unknown. A better
understanding could lead to novel therapeutic approaches to improve immune function in
patients suffering from various diseases.
The investigators have found that hypertonic conditions regulate leukocyte functions through
feedback mechanisms involving ATP release and purinergic receptors. The purpose of the
proposed protocol is to obtain access to peripheral blood from healthy volunteers to study
these complex regulatory mechanisms in more detail.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03242395 -
PRIME: Cognitive Outcome Following Major Burns
|
N/A | |
Recruiting |
NCT04032626 -
MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients
|
Phase 2 | |
Completed |
NCT04002219 -
Efficacy Evaluation of the Mushroom Beverage on Emotion Regulation
|
N/A | |
Not yet recruiting |
NCT06177028 -
MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease
|
Phase 2 | |
Active, not recruiting |
NCT05515640 -
Dysautonomia and Systemic Interactions in Traumatic Brain Injury
|